DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Swain S, Kim S, Cortes J et al.
Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1 L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology 2014; Abstr. #350O_PR.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.